Naloxone intranasal - Mundipharma International

Drug Profile

Naloxone intranasal - Mundipharma International

Alternative Names: Nyxoid

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mundipharma International
  • Class Antidotes; Morphinans; Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Opioid abuse

Most Recent Events

  • 15 Sep 2017 The Committee for Medicinal Products for Human Use (CHMP) recommends granting approval for naloxone intranasal spray for Opioid abuse in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top